EF Hutton analyst Tim Moore lowered the firm’s price target on CEL-SCI to $16 from $17 and keeps a Buy rating on the shares following the fiscal 2022 results. The company did not generate any revenues and is not expected to over the next several quarters, Moore tells investors in a research note. The analyst, however, remains "optimistic that positive news flow about the Multikine immunotherapy could unfold over the next several months."
Published first on TheFly
